Skip to content

HPV Prevalence in 16-20 Year Old Males

Evaluation of the Impact of Quebec HPV Immunization Program: Prevalence of HPV Types in 16-20 Year Old Males

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT04297670
Enrollment
681
Registered
2020-03-05
Start date
2020-02-20
Completion date
2020-12-31
Last updated
2020-03-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

HPV Infection

Keywords

Prevalence, Boys

Brief summary

In Quebec, 18 birth cohorts of girls were vaccinated against HPV (aged 9 to 29 years in 2020). With an observed vaccination coverage of \>80% an important herd effect might be expected. This study aim is to measure the HPV types prevalence in unvaccinated sexually active boys aged 16 to 20 years.

Detailed description

An HPV immunization program is in place in Quebec since 2008. By 2020 18 birth cohorts of girls were eligible for vaccination. Vaccine uptake with at least one dose of vaccine was \>80%. With such a high vaccine uptake an important herd immunity might be expected. The main objective of this study is to measure the prevalence of different HPV types in unvaccinated sexually active boys aged 16 to 20 years. This is a cross sectional study which includes one visit for all participants. Self sampling technic is used. During this phase of the study a total of 681 boys will be recruited. An additional phase of the study will be conducted at the condition that the prevalence of HPV6/11/16/18/31/33/45/52 and 58 in unvaccinated boys will be at least 8.65%. The second phase of the study if conducted will measure the prevalence of the same HPV types in 681 vaccinated boys of the same age.

Interventions

OTHERMeasurement of HPV types prevalence

Self collected genital samples to be tested for the presence of different HPV types.

Sponsors

Laval University
Lead SponsorOTHER

Study design

Observational model
ECOLOGIC_OR_COMMUNITY
Time perspective
CROSS_SECTIONAL

Eligibility

Sex/Gender
MALE
Age
16 Years to 20 Years
Healthy volunteers
Yes

Inclusion criteria

* unvaccinated against HPV * sexually active

Exclusion criteria

* received an HPV vaccine * non sexually active

Design outcomes

Primary

MeasureTime frameDescription
Prevalence of HPV 6/11/16/18/31/33/45/52 and 58Up to 18 monthsUnvaccinated sexually active 16-20 year old boys will be tested

Secondary

MeasureTime frameDescription
Prevalence of 31 HPV typesUp to 18 monthsUnvaccinated sexually active 16-20 year old boys will be tested

Countries

Canada

Contacts

Primary ContactChantal Sauvageau, MD, MSc
chantal.sauvageau@inspq.qc.ca1 418 650 5115
Backup ContactVladimir Gilca, MD, PhD
vladimir.gilca@inspq.qc.ca1 418 650 5115

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026